Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OKN4395 Alone and With Pembrolizumab in Advanced Solid Tumors
NCT06789172Phase 1Recruiting
- Sponsor
- Nanjing Epkin Biotechnology Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of okn4395 in solid tumor, sarcoma, non-small cell lung cancer (NSCLC) and 2 more (7 arms), sponsored by Nanjing Epkin Biotechnology Co., Ltd. Primary endpoints: Dose-Limiting Toxicities up to 27 months, Treatment-Emergent Adverse Events up to 12 months and 7 more. Started Jan 2025; status: recruiting.
02
Drugs
okn4395
03
Conditions
solid tumorsarcomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06789172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789172.